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ABSTRACT
Differential Microglial Responses Induced by N-α-Synuclein-Specific Effector T Cell Clones
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Parkinson’s disease (PD) is the most common neurodegenerative movement disorder. Characteristic
PD symptoms are due to the deficiency of dopamine neurotransmitter resulting from the loss of
dopaminergic neurons that originate in the substantia nigra pars compacta (SNpc) and innervate to the
caudate putamen. Hallmarks of PD include neuroinflammation and accumulation of misfolded and
modified self-proteins, mostly α−synuclein, as intraneuronal inclusions or Lewy bodies.
Neuroinflammation is mediated by microglia which are activated by release of misfolded and modified α-
synuclein to the surrounding brain tissues following neuronal death. Activated microglia secrete
proinflammatory cytokines and mediators which increase inflammation, and oxidative modification and
accumulation of self-proteins, and neuronal toxicity. Additionally, modified α-synuclein and
proinflammatory mediators traffic to the lymph nodes and induce effector T cells (Teffs) that recognize
modified epitopes on α-synuclein. We showed that CD4+ T helper type 1 and type 17 (Th1 and Th17)
cells traffic back to the inflammatory foci in the brain and exacerbate the cycle of neuroinflammation-
protein misfolding-neurodegeneration by hyper-activating microglia to higher states of neurotoxicity. In
an animal model of PD, Th17 Teffs proved to exacerbate neurotoxicity to greater levels than Th1 cells,
however the mechanism by which those Teff lineages function remain enigmatic. To determine whether
these Teff types were killing neurons either through direct-mediated killing mechanisms or by indirectly
hyper-activing microglia to neurotoxic levels, we developed three long-term stable Teff clones that
recognize nitrated-α-synuclein (N-α-syn) as a modified self-antigen present in PD. These were
phenotypically and functionally characterized as Th1, Th17, and a hybrid Th17.1 clonotypes, and
displayed increasing dopaminergic neurotoxicity associated with their phenotype, respectively.
The purpose of these studies was to assess differential cytokine responses by BV-2 microglia co-
cultured with each activated Th1, Th17, or Th17.1 N-α-syn specific, clonotypic Teff.
T cell lines and BV-2 microglia culture. Cells of the microglial cell line BV-2 were cultured in
complete DMEM supplemented with 5% FBS. Effector T cell (Teff) lines were derived from mice
immunized and boosted with nitrated-α-synuclein (N-α-syn). Lines were cloned and maintained in
excess of 8 months by weekly subculture in complete RMPI-1640 supplemented with 10% FBS, 30
μg/ml of N-α-syn, 20 x 106 irradiated syngeneic APCs, and a cocktail of Teff-type selection cytokines
and antibodies (Reynolds et al., 2010). Media for Th1 Teffs was supplemented with 25 U/ml IL-2; for
Th17 Teffs media contained TGF-β, IL-6, IL-1β, IL-23, anti-IL-4, anti-IFN-ɣ, and anti-IL-2; and for
Th17.1, media contained TGF-β, IL-6, IL-1β, IL-23, and IL-2 (Wilshusen et al., unpublished results)
Th1, Th17, and Th17.1 were activated for 30 minutes by stimulation with anti-CD3/anti-CD28
transactivation beads (Dynabeads) at a 1:1 ratio of bead:cell and excess beads removed. Activated
Teffs were added to BV-2 microglia and co-cultured at a 1:1 ratio of T cell:microglia. Teffs from each
T cell line, Th1, Th17, and Th17.1, were co-cultured for with BV-2 microglia in duplicate for 24
hours, after which Teffs and supernatant were removed, fresh media replaced, and adherent BV-2
microglia cultured for 24 hours before removing culture supernatants for evaluation of cytokine
levels. BV-2 microglia cultured in the absence of Teffs served as controls.
Cytokine array assay. Supernatants from BV-2 microglia treated with activated Th1, Th17, Th17.1 or
media alone (Control) were analyzed for cytokine type and relative level by cytokine membrane
assay (Mouse Inflammatory Antibody Array, ab197473-40, AbCam, Cambridge, MA) containing
cytokine targets and controls performed by the manufacturer’s instructions. Membranes were
visualized with fluorescence probes and relative fluorescence intensities were measured using a
microarray scanner (GenePix 4000B Microarray Scanner, Molecular Devices). Relative intensities
were determined by digital image analysis using Image J (National Institutes of Health)
Statistics. Significant differences in means of relative intensities of cytokine measurements were
determined for control-, Th1-, Th17-, or Th17.1-treated BV-2 microglia by one way ANOVA with
Fisher’s LSD post hoc analyses. P values were adjusted to control for false discovery rate by the
procedure of Benjamini, Krieger, and Yekutieli.




Figure 1. Cytokines from Teff-treated BV-2 microglia. BV-2 microglia were co-
cultured with activated Th1, Th17, or Th17.1 Teff clones specific for N-a-
synuclein, or remained untreated (Control). After Teffs and supernatants were
removed, BV-2 microglia were cultured for 24 hours and supernatant assessed
for expression of cytokines by antibody capture membrane array for (A)
interleukins (B) chemokines, and (C) the factor group including TNF, IFN, and
CSF families (Mouse Inflammatory Antibody Array, ab197473-40, AbCam).
Significant differences between means (± SEM) for relative intensities of cytokine
responses, where P < 0.05 compared to BV-2 microglia cultured with amedia
(Control), bTh1 Teffs, or cTh17 Teffs.
Compared to controls, treatment with Th1 Teffs, significantly increased levels of
8/12 interleukins (A), 12/14 chemokines (B), and 10/13 group factors (C).
Treatment with Th17 Teffs increased levels in 11/12 interleukins (A), 11/14
chemokines (B), and 12/13 grouped factors (C). Treatment with Th17.1 Teffs
increased levels in 12/12 interleukins (A), 13/14 chemokines (B), and 12/13
grouped factors (C)
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A B C Figure 2. Comparative cytokine expression by BV-2 microglia after
treatment with Teff clones. (A) BV-2 microglial cytokine responses were
normalized to control levels and converted to heat maps. From those maps,
we identified cytokines that were significantly increased by at least 2-fold
and at the P < 0.01 confidence level. Those analyses indicated that Th1
Teff treatment of BV-2 microglia induced increases in MIG, IFN-γ, RANTES,
Fas Ligand, IL-17, Eotaxin-1, and Leptin. Th17 Teff treatment induced
TIMP-1, SDF-1, TECK, IL-17, TNFα, TIMP-2 and KC to those levels.
Treatment with Th17.1 Teffs induced greater than 2-fold increases in TIMP-
1, SDF-1, and IL-12 p40/p70. (B) To compare responses induced by Th1
Teffs to those induced by Th17 and Th17.1 Teffs, we normalized the latter
two responses to those induced by Th1. Compared to Th1 responses,
similar diminutions were noted in Th17- and Th17.1-induced production of
RANTES, IFN-γ, and MIG with similar increases in MIP-1α and TIMP-1
production. Also detected were increased levels of BLC, Fractalkine, TECK,
TNF-α, G-CSF, and GM-CSF, by Th17-treated microglia, whereas Th17.1
Teffs increased IL-12 and SDF-1 levels. (C) Since Th17.1 was derived
from the Th17 clone, we assessed the relative response induced by Th17.1
and normalized to that of Th17. Analyses indicated a profound comparative
diminution of many cytokines, but showed a definitive profile of increased
production of IL-12p40/p70 and RANTES.
• This study confirms that Th1 and Th17 Teffs that recognize the modified self protein N-α-synuclein upregulates proinflammatory cytokine
production by BV-2 microglia and demonstrates the proinflammatory potential for a novel Th17.1 Teff clone.
• Co-culture of clonotypic Teffs produced differential cytokines responses by BV-2 microglia. Th1 Teffs led to higher expression of IFN-𝛾𝛾,
RANTES, and MIG.
• Th17 or Th17.1 co-culture led to higher expression of TIMP-1 and SDF-1, while Th17 yielded higher expression of TECK, IL-17, TNF- α,
and KC (CXCL1), whereas Th17.1 induced higher levels of RANTES and IL-12 p40/p70 simiar to Th1 Teffs. .
• IPA demonstrated microglial pathways increased in cellular movement, hematological system development and function, and immune
cell trafficking for Th1 and Th17 Teffs, while Th17.1 treatment yielded pathways related to disorder of connective tissue, inflammation,
and organismal injury.
• Future studies from these observations may identify and target specific cytokine pathways targeted to inhibit neuroinflammation and
neuronal cell death.
Figure 3. Differential pathways induced by Th1, Th17, and Th17.1 Teffs. Expression profiles from BV-2 microglia cytokine responses to Th1, Th17,
and Th17.1 Teffs were normalized to Control (Figure 2A). Profiles of cytokines that were expressed above or below 2-fold and at significance levels
below 0.01 were entered into and evaluated by Ingenuity Pathway Analysis (IPA). Overall, Th1 and Th17 upregulated similar network pathways
including cellular movement, hematological system development and function, and immune cell trafficking. Thus, increasing the stimulation and
production of further inflammatory mediating cells and increasing chemotaxis and tissue extravasation of these inflammatory cells. Interestingly, Th17.1
upregulated pathways associated with connective tissue disorders, inflammatory diseases, and organismal injury and abnormalities.
Th1-Induced Pathways. For Th1 treated BV-2 microglia, MIG (CXCL9) displayed the most substantial expression change at a 13.3 relative to control,
with IFN-γ, RANTES (CCL5), Fas Ligand, IL-17, Eotaxin (CCL11) and Leptin completing the profile of response that is programed to promote MIHC
presentation, chemotaxis of other leukocytes, killing activity, induction of apoptosis.
Th17- and Th17.1-Induced Pathways. Pathways for Th17- and Th17.1-treated BV-2 microglia showed high levels of TIMP-1 and SDF-1. TIMP-1 is a
matrix metalloproteinase inhibitor that is associated with attenuation of inflammatory responses and may play a compensatory regulatory role. Stromal
cell-derived factor 1 (SDF-1, CXCL12) is a potent chemotactic agent for lymphocytes and has been shown to play a role in neurogenesis and
neuroinflammation.
Co-culture with Th17 Teffs induced BV-2 microglia to produce TECK (CCL25) and KC (CXCL1); both chemotactic factors for macrophages/dendritic
cells and neutrophils, respectively. Th17 Teffs also induced TNFα a known proinflammatory cytokine and inducer of apoptosis. Microglial-derived IL-17
induces other chemokines and exacerbates neuroinflammation and with TNFα kills dopaminergic neurons.
Co-culture with Th17.1 Teffs induced BV-2 microglial production to not only secrete TIMP-1 and SDF1 as with Th17 Teffs, but in contrast induced also
production of RANTES and IL12p40/p70 as was induced by Th1 Teffs.
Parkinson’s disease (PD) is a
neurodegenerative movement disorder in which
symptoms derive from deficits in dopamine
neurotransmitter levels secondary to loss of
dopaminergic neurons in the substantia nigra
pars compacta (SNpc) associated with
misfolding and accumulation of α-synuclein.
Neuroinflammation via microglia and T effector
cells (Teffs) contribute to dopaminergic
neuronal cell death. Recognition of cytokine
profiles of pro-inflammatory microglia is not well
understood and serve as potential therapeutic
targets to reduce neuroinflammation. Recent
studies demonstrated a novel Th17.1 Teff
clonotype increases neurotoxicity. The aim of
this study was to demonstrate in vitro cytokine
responses by BV-2 microglia induced by Th1,
Th17, and Th17.1 clonotypes to assess
neuroinflammation mechanisms in PD.
Cytokine responses by BV-2 microglia co-
cultured with activated Teff clonotypes were
analyzed using a cytokine membrane
array. Co-culture with Teffs led to significant
increases in the majority of cytokine responses
from BV-2 microglia compared to control. Cross
group analysis relative expression
demonstrated variation in cytokine profiles
produced between microglia treated with
different Teff clonotypes, especially with regard
to IFNγ, MIG, MIP-1α, TIMP-1, RANTES, SDF-
1, and IL-12 p40/p70. Ingenuity Pathway
Analysis (IPA) of cytokines displaying
significant relative expression levels for each
Teff clonotype showed Th1- and Th17- treated
BV-2 microglia demonstrated pathways related
to cellular movement, hematological
development and function, and immune
trafficking while Th17.1-treated microglia
upregulated pathways related to disorders of
connective tissue, inflammation, and
organismal injury. In conclusion, Th1, Th17,
and Th17.1 Teffs treatment of BV-2 microglia
led to upregulation of most pro-inflammatory
cytokines and pathways. However, specific Teff
clonotype culture with BV-2 microglia displayed
differing cytokine profile responses through
varying relative expression profiles with
significant differences related to IFNγ, MIG,
MIP-1α, TIMP-1, RANTES, SDF-1, and IL-12
p40/p70 delineating alternative inflammatory
pathways. These results provide relevant
targets for strategies to attenuate
neuroinflammation and protect dopaminergic
neurons in PD
